Alkem Laboratories Ltd Share Price

Overview

Alkem Laboratories Ltd share price is currently ₹5,309.87, up by ₹32.35 (0.61%) from its previous closing price of ₹5,277.52. The share price has declined -3.43% over the past month and gained 0.17% over the past year. The stock's 52-week low and high are ₹0.00 and ₹5,859.36, respectively. Alkem Laboratories Ltd has a market capitalisation of ₹ 64,570.00 Cr. The share price was last updated on 25 Aug 2026, 03:59 PM IST.

Alkem Laboratories Ltd

ALKEM

₹0.00

₹32.35

0.61%

Healthcare

₹0.00(%)1D

Updated: 25 Aug 2026, 03:59:56 pm IST

Market Data

Open Price

₹5,291.77

Prev. Close

₹5,277.52

₹5,238.00

Day Low

₹5,309.87

Day High

₹0.00

52 Week Low

₹5,859.36

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

29.42

Sector PE

42.03

PB Ratio

4.61

Sector PB

5.82

EPS

180.47

Dividend Yield

1.00

Today's Volume

48.038 K

5 Day Avg. Volume

94.168 K

PEG Ratio

4.67

Market Cap.

₹ 64,570.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 500% at ₹10/Share	07-Aug-2026	07-Aug-2026
DividendsInterim Dividend of 2150% at ₹43/Share	20-Feb-2026	20-Feb-2026
DividendsFinal Dividend of 400% at ₹8/Share	08-Aug-2025	08-Aug-2025
DividendsInterim Dividend of 1850% at ₹37/Share	14-Feb-2025	14-Feb-2025

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
HDFC Mid Cap Fund - Regular Plan - Growth	31.61 Lac	31.61 Lac no change
ICICI Prudential Multi-Asset Fund - Growth	15.50 Lac	15.50 Lac no change
SBI Large & Midcap Fund - Regular Plan - IDCW	14.77 Lac	14.77 Lac no change
Nippon India Growth Mid Cap Fund - Growth Option	11.63 Lac	11.63 Lac no change
Axis Midcap Fund - Regular Plan - Growth	5.19 Lac	8.92 Lac (71.76%)

Show all holdings

About Alkem Laboratories Ltd 👋

Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company's subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.